Redirecting T Cells with Chimeric Antigen Receptor (CAR) for the Treatment of Cancer
A special issue of Antibodies (ISSN 2073-4468). This special issue belongs to the section "Antibody-Based Therapeutics".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 307
Special Issue Editors
Interests: tumor microenvironment; tumor immunity; cancer immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
As an effective approach to modulate adaptive immunity, chimeric antigen receptor (CAR) T-cell therapy has revolutionized the paradigm in leukemia treatment, driving an ever-expanding body of basic and clinical research on CAR T cells to treat patients with other types of cancer. The convergence of genome engineering and CAR T-cell therapy technology holds great potential for the generation of a new class of cellular therapeutics. Meanwhile, the clinical application of CAR T-cell therapy remains limited on account of antigen escape and heterogeneity, physical and immune barriers, and on-target off-tumor toxicity. Although several advances have been made in CAR-T therapies, the development of engineered T cells against malignancies remains challenging due to the similarities between normal and tumor cells, the compacted tumor microenvironment, and so on. Understanding the evolution of CAR structure and the generalizable requirements for manufacturing CAR T cells, as well as the interplay between CAR T cells and tumor immunology, will promote the clinical translation of this therapeutic modality.
Dr. Xuyao Zhang
Dr. Xin He
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CAR T cells
- Antigen escape
- Immunosuppressive tumor microenvironment
- Novel tumor target
- Genome engineering
- Cell therapy technology
- Novel strategies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
